DCAL
Dishman Carbogen Amcis Limited (DCAL) Stock Analysis
Dishman Carbogen Amcis Limited is an Indian contract research and manufacturing organisation for pharma. It produces APIs and intermediates for global innovators from facilities in India and Europe. CDMO demand and complex chemistry capabilities support its business. The company is listed on Indian stock exchanges and operates from India.
Healthcare › Biotechnology
₹164.30
-3.65% 1W | -37.80% 52W
Market Cap
2.6k CR
P/E Ratio
26.4
52W High
₹306
52W Low
₹128.5
Div. Yield
0%
Beta
0.6
50 DMA
₹178.6
200 DMA
₹189.2
Profit Margin
0.6%
Inst. Own.
2.7%
⚡ APPROACHING SUPPORT
⚡ APPROACHING SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 723 | 587 | 651 | 655 | 524 | 789 | 682 | 716 | 708 | 653 | 720 | 851 | 678 |
| Expenses | 602 | 526 | 610 | 592 | 495 | 642 | 542 | 564 | 567 | 504 | 607 | 688 | 618 |
| Operating Profit | 122 | 61 | 41 | 63 | 29 | 147 | 140 | 153 | 141 | 149 | 113 | 163 | 60 |
| OPM % | 17% | 10% | 6% | 10% | 6% | 19% | 21% | 21% | 20% | 23% | 16% | 19% | 9% |
| Other Income | 7 | 5 | 6 | 4 | -4 | 4 | 8 | -4 | 22 | 8 | 7 | 15 | 16 |
| Interest | 28 | 27 | 33 | 31 | 32 | 37 | 49 | 42 | 43 | 42 | 46 | 43 | 37 |
| Depreciation | 70 | 75 | 80 | 85 | 71 | 72 | 72 | 79 | 81 | 84 | 84 | 89 | 91 |
| Profit before tax | 29 | -36 | -66 | -49 | -78 | 42 | 27 | 28 | 39 | 31 | -10 | 46 | -51 |
| Tax % | 42% | 13% | -10% | 42% | 0% | 21% | 83% | -56% | 39% | -114% | 24% | 53% | 13% |
| Net Profit | 17 | -41 | -60 | -70 | -78 | 33 | 5 | 43 | 23 | 65 | -13 | 22 | -58 |
| EPS in Rs | 1.08 | -2.61 | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 | 2.75 | 1.49 | 4.16 | -0.83 | 1.39 | -3.69 |
| Metric | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,031 | 1,714 | 1,695 | 2,059 | 2,044 | 1,912 | 2,141 | 2,413 | 2,616 | 2,712 | 2,932 | 2,901 |
| Expenses | 830 | 1,261 | 1,249 | 1,507 | 1,540 | 1,638 | 1,809 | 2,081 | 2,329 | 2,243 | 2,366 | 2,416 |
| Operating Profit | 201 | 452 | 445 | 552 | 503 | 274 | 331 | 332 | 286 | 469 | 566 | 485 |
| OPM % | 20% | 26% | 26% | 27% | 25% | 14% | 15% | 14% | 11% | 17% | 19% | 17% |
| Other Income | 14 | 26 | 46 | 54 | 39 | 16 | 29 | -20 | 22 | 4 | 52 | 47 |
| Interest | 56 | 49 | 49 | 57 | 62 | 48 | 57 | 86 | 120 | 159 | 174 | 169 |
| Depreciation | 69 | 214 | 211 | 240 | 283 | 308 | 308 | 281 | 311 | 294 | 339 | 348 |
| Profit before tax | 91 | 216 | 231 | 309 | 197 | -65 | -4 | -55 | -122 | 19 | 105 | 15 |
| Tax % | 12% | 33% | 33% | 32% | 20% | 154% | -524% | -45% | 26% | 83% | 7% | |
| Net Profit | 80 | 145 | 155 | 210 | 159 | -165 | 18 | -30 | -153 | 3 | 97 | 16 |
| EPS in Rs | 9.58 | 13.03 | 10.10 | -10.53 | 1.15 | -1.90 | -9.79 | 0.21 | 6.22 | 1.03 | ||
| Dividend Payout % | 0% | 0% | 0% | 2% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 7.0% | 9.0% | – |
| Profit CAGR | 140.0% | 21.0% | – |
Shareholding Pattern
Promoters59.32%
FIIs9.94%
DIIs1.27%
Public29.48%
Promoters59.32%
FIIs8.07%
DIIs1.37%
Public31.23%
Promoters59.32%
FIIs7.66%
DIIs1.27%
Public31.75%
Promoters59.32%
FIIs7.45%
DIIs1.63%
Public31.60%
Promoters59.32%
FIIs6.86%
DIIs2.06%
Public31.76%
Promoters59.32%
FIIs9.34%
DIIs2.55%
Public28.79%
Promoters59.32%
FIIs8.70%
DIIs2.36%
Public29.63%
Promoters59.32%
FIIs9.49%
DIIs1.26%
Public29.94%
Promoters59.32%
FIIs7.45%
DIIs1.63%
Public31.60%
Promoters59.32%
FIIs6.86%
DIIs2.06%
Public31.76%
DCAL
Holdings Analysis
Key strengths & risk signals
56
Overall
63
Fundamental
49
Technical
Risks (4)
LOW MARGIN! 0.6% profit margin - thin profits.
POOR YEAR! Stock declined 37.8% in the last year.
WEAK POSITION! Current price (164.3) is below both moving averages.
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.6% (1 week), 6.0% (1 month), 6.3% (3 months).
Strengths (4)
FAIRLY VALUED! PEG of 1.26 indicates reasonable valuation.
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
APPROACHING OVERSOLD! RSI at 38.9 - watch for reversal.
BULLISH SENTIMENT! In last 30 days: 11 up days, 18 down days. Avg volume on up days: 370,855 vs down days: 336,339. Ratio: 1.1x
Fundamental & Technical Analysis
56Overall
63Fundamental
49Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 9.0% (MODERATE, 8/15). Profit CAGR: 21.0% (EXCELLENT, 15/15).
Profit Margin
2/10
LOW MARGIN! 0.6% profit margin - thin profits.
PEG Valuation
9/10
FAIRLY VALUED! PEG of 1.26 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 28.65% public ownership - balanced ownership structure.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (178.6) is below 200-day average (189.2) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (164.3) is below both moving averages.
Trend Pattern
10/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
0/10
POOR YEAR! Stock declined 37.8% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 11 up days, 18 down days. Avg volume on up days: 370,855 vs down days: 336,339. Ratio: 1.1x
RSI
4/5
APPROACHING OVERSOLD! RSI at 38.9 - watch for reversal.
52W Range
2/5
LOWER HALF! Trading at 20.2% of 52W range - weakness visible.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.6% (1 week), 6.0% (1 month), 6.3% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
DCAL
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-25 | Concall PDF | |
| Q3FY262026-02-10 | Concall PDF | |
| Q2FY262025-11-11 | Concall PDF |
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DCAL | ₹164.30 | 26.4 | 0.6% | 9.0% | 21.0% | -37.8% | 56 | APPROACHING SUPPORT | -347.9% | -367.3% | -4.2% | -20.4% |
| PANACEABIO | ₹366.40 | – | -1.1% | 10.1% | – | -8.2% | 53 | CONSOLIDATING DOWN | -42.5% | +360.0% | +19.7% | +19.7% |
| ZOTA | ₹1,322.20 | – | -17.0% | 56.7% | – | -4.6% | 60 | BREAKOUT | +204.9% | +207.0% | +67.6% | +6.4% |
| HALEOSLABS | ₹1,513.50 | 29 | 4.9% | 0.3% | 14.7% | +33.2% | 67 | BREAKOUT | -38.1% | +550.0% | -11.6% | -2.9% |
| LYKALABS | ₹84.10 | – | -6.6% | 13.3% | – | -10.2% | 59 | CONSOLIDATING UP | +133.3% | -127.6% | +28.2% | +51.1% |
| 3BBLACKBIO | ₹1,584.80 | 23.9 | 36.3% | 31.9% | 32.2% | +26.8% | 77 | BREAKOUT | -24.6% | -1.0% | +50.9% | -5.4% |
| SUPRIYA | ₹984.80 | 40 | 22.7% | 21.2% | 32.5% | +36.1% | 83 | BREAKOUT | -31.0% | -67.7% | +30.7% | -31.4% |
| BLUEJET | ₹557.30 | 41.2 | 26.5% | 9.4% | 15.7% | -10.8% | 72 | BREAKDOWN | -14.1% | +21.8% | -17.4% | +24.9% |
Data from TradeAlone · Updated daily
DCAL News
Dishman Carbogen Amcis Limited (dcal) Q1fy27: Net Revenue Dips, CDMO Segment Struggles2026-08-17Dishman Carbogen Amcis Limited DCAL: Carbogen AMCIS AG Commissions 1,200 Kwp Solar Power Plant2026-06-29Dishman Carbogen Amcis Limited (dcal) Q4fy26: Revenue Surges 18.9%, PAT Up 446%2026-05-20Dcal Subsidiary Achieves Successful Gmp Inspection in China2026-05-05
